Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 2
2008 5
2009 5
2010 7
2011 13
2012 7
2013 10
2014 20
2015 10
2016 9
2017 9
2018 5
2019 6
2020 2
2021 4
2022 9
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23723317

112 results

Results by year

Filters applied: . Clear all
Page 1
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Porter D, et al. Lancet. 2016 Jul 16;388(10041):239-47. doi: 10.1016/S0140-6736(16)00380-9. Epub 2016 May 17. Lancet. 2016. PMID: 27197690 Free article. Clinical Trial.
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis NB, Williams S, Reynard M, Tyrrell H. Emery P, et al. Rheumatology (Oxford). 2011 Dec;50(12):2223-32. doi: 10.1093/rheumatology/ker253. Epub 2011 Sep 16. Rheumatology (Oxford). 2011. PMID: 21926153 Free PMC article. Clinical Trial.
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H. Emery P, et al. Ann Rheum Dis. 2010 Sep;69(9):1629-35. doi: 10.1136/ard.2009.119933. Epub 2010 May 20. Ann Rheum Dis. 2010. PMID: 20488885 Free PMC article. Clinical Trial.
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM; MIRROR Trial Investigators. Rubbert-Roth A, et al. Rheumatology (Oxford). 2010 Sep;49(9):1683-93. doi: 10.1093/rheumatology/keq116. Epub 2010 May 12. Rheumatology (Oxford). 2010. PMID: 20463186 Free PMC article. Clinical Trial.
112 results